Mental illness research hit by funding crisis

By Admin
Scientists are warning that research into mental illnesses such as depression and schizophrenia is facing a ‘funding crisis. Pharmaceutical compa...

Scientists are warning that research into mental illnesses such as depression and schizophrenia is facing a ‘funding crisis’.

Pharmaceutical companies including GlaxoSmithKline and AstraZeneca recently announced that there were no longer any plans for them to participate in research for new anti-depressant drugs.

 A report by the European College of Neuropsychopharmacology is warning that as a result there will be a delay in the development of new treatments for mental illnesses as well a lack in available training for the next generation of neuroscience researchers.


To read the latest edition of Healthcare Global, click here

In Europe, approximately 80 percent of funding for brain research into mental illnesses had come from the private sector.

However, pharmaceutical companies were increasingly withdrawing their support as a result of the huge cost that is involved in introducing new drugs and treatments to the consumer.

On average it takes about 13 years for drug treatments for mental illness to be developed and agomelatine is the only anti-depressant that has been approved in Europe in the last 10 years.

Professor Guy Goodwin from the University of Oxford is calling for more money to be invested in brain research: “The cost and burden are really quite high, yet research attracts disproportionately low investment,” he said in an interview.

“Public investment in research should be somehow related to the burden of the disease.”

He also believes that this funding crisis will have a negative impact on the neuroscience research and training and will result in a “generational crisis.”

Meanwhile, Professor David Nutt from Imperial College London said: “With Europe's extraordinary tradition in neuroscience innovation relying so heavily on private-sector investment, the consequences for the region's research base and public-health agenda are of major concern.”


Featured Articles

Why clinical AI is the future of healthcare

Harish Battu from General Catalyst explores the use of AI in healthcare, the challenges of its adoption & what it means for healthcare technology

AI can help healthcare workers deliver compassionate care

Dr. Lance Owens, Chief Medical Information Officer at the University of Michigan Health-West, explains how AI technology can support healthcare workers

Digital healthcare platform Balanced supports healthy ageing

10,000 people turn 65 in the USA each day. Digital healthcare platform Balanced wants to help them better manage healthy ageing, says CEO Katie Reed

TrueBinding’s antibody drugs fight Alzheimer’s Disease

Medical Devices & Pharma

Cardinal Health’s clinically integrated pharma supply chain

Medical Devices & Pharma

Healthcare Digital news roundup: digital healthcare & AI

Digital Healthcare